Care In Heart Failure Clinic Staffed By Advanced Practice Providers Is Associated With Higher Prescription Rates For Guideline-directed Medical Therapy

John T. Menchaca,Franck Azobou Toneu,Martin Campbell,Tre'cherie Crumbs,Anita Osabutey,Alexis Okoh,Modele Ogunniyi

DOI: https://doi.org/10.1016/j.cardfail.2023.10.298

IF: 6.592

2024-01-01

Journal of Cardiac Failure

Abstract:Introduction Heart failure with reduced ejection fraction (HFrEF) is a leading cause of morbidity and mortality. In practice, recommended guideline-directed medications are often not started and not titrated to target dose. Novel solutions are needed to optimize treatment regimens and care outcomes in our large public safety net hospital system. Hypothesis Regular care at a heart failure clinic staffed by advance practice providers (APPs) with supervision by a cardiologist is associated with higher prescription and target dosing rates for the primary GDMT medication classes, including ACEi/ARB/ARNi, beta blockers (BB), MRA, and SGLT2i. Methods We identified patients from 2015-2022 with 1) lowest recorded LVEF ≤40%, 2) ≥1 cardiology or primary care visit within the last 2 years, and 3) ≥1 active medication prescription. We used multivariate logistic regression to estimate the association between ≥2 heart failure clinic visits in the last 2 years (“HF clinic care”) and the likelihood of a patient having an active GDMT prescription. We adjusted the model for lowest recorded LVEF, most recent LVEF, total admissions in the last 2 years, total primary care and general cardiology clinic visits in the last 2 years, insurance type, and kidney function. Results Among 2,864 patients meeting criteria for inclusion, 840 (29.3%) received HF clinic care. Patients receiving HF clinic care had a median of four HF clinic visits and were more likely to have a lower LVEF, more admissions, and fewer primary care visits. Total general cardiology visits were similar between groups. The adjusted odds ratio [95% CI] for active GDMT prescription for patients receiving HF clinic care are: ACEi/ARB/ARNi 1.1 [0.9, 1.4], BB 1.4 [1.1, 1.9], MRA 1.5 [1.3, 1.9], and SGLT2i 2.5 [2.1, 3.1] (Figure 1). For target dosing of GDMT, the adjusted odds ratio confidence intervals for patients receiving HF clinic care include 1 for ACEi/ARB/ARNi, BB, and MRA and was 2.5 [2.1, 3.1] for SGLT2i. Conclusions Patients with HFrEF receiving supplemental care in a heart failure clinic staffed by APPs and supervised by cardiologists are more likely to have prescriptions for multiple GDMT medications. This care is not associated with higher likelihood of medication prescriptions at target dose for BB, ACEi/ARB/ARNI or MRA.

cardiac & cardiovascular systems